1. |
[1]Beller. George A. Coronary Heart Disease in the First 30 Years of the 21st Century: Challenges and Opportunities: The 33rd Annual James B. Herrick Lecture of the Council on Clinical Cardiology of the American Heart Association[J]. Circulation,2001 ;103(20) :2 428-2 435.
|
2. |
[2]Wang L, Zhai AP, Chai XS. The Vitro Action of Purarin On Cats Vascular Smooth Muscle[J]. Acta Pharmacologica Sinica,1994;15(2) :180 -182.
|
3. |
[3]Zhou JH, Zhou H, Liu XR. Effet of Purarin Injection on Blood Fat and Hemotheology[J]. J Med Thero & Prac, 2000;13(1) :40.
|
4. |
[4]Clarke M, Oxman AD, editors. Cochrane Reviever’ s handbook 4.1 [ M/CD ] [ Update 2000 ]. In Review Manager (RevMan) [ Computer program], Version4.1. Oxford, England: The Cochrane Collaboration, 2000.
|
5. |
[5]Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,Gavaghan DJ, McQuary HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary [ J ] ? Controlled Clin Trials, 1996 ; 17(1): 1-12.
|
6. |
[6]Liu M, Zhang SH. New Knowledge: Intention-to-Treat Analysis in Clinical Trail[J]. BMJ Chinese Edition, 2001;4(4) :223 -224.
|
7. |
劉鳴,張世洪.新知識:臨床試驗中的意向處理分析[J].英國醫學雜志中文版,2001;4(4):223~224.
|